Viktoryia Sidarovich

Viktoryia Sidarovich

Auto-generated profile, based on publicly available information

Viktoryia Sidarovich

Laboratory of Translational Genomics, Centre for Integrative Biology, University of Trento, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GOGianluca Occhi
Gianluca Occhi
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
GTGiampaolo Trivellin
Giampaolo Trivellin
FBFrancesca Boaretto
Francesca Boaretto
DCDenis Ciato
Denis Ciato
CSCarla Scaroni
Carla Scaroni
The CDKN1B gene encodes the cyclin-dependent kinase inhibitor p27KIP1, an atypical tumor suppressor playing a key role in cell cycle regulation, cell proliferation, and differentiation. Impaired p27KIP1 expression and/or localization are often observed in tumor cells, further confirming its central role in regulating the cell cycle. Recently, germline mutations in CDKN1B have been associated with the inherited multiple endocrine neoplasia syndrome type 4, an autosomal dominant syndrome characterized by varying combinations of tumors affecting at least two endocrine organs. In this study we identified a 4-bp deletion in a highly conserved regulatory upstream ORF (uORF) in the 5′UTR of the CDKN1B gene in a patient with a pituitary adenoma and a well-differentiated pancreatic neoplasm. This deletion causes the shift of the uORF termination codon with the consequent lengthening of the uORF–encoded peptide and the drastic shortening of the intercistronic space. Our data on the immunohistochemical analysis of the patient's pancreatic lesion, functional studies based on dual-luciferase assays, site-directed mutagenesis, and on polysome profiling show a negative influence of this deletion on the translation reinitiation at the CDKN1B starting site, with a consequent reduction in p27KIP1 expression. Our findings demonstrate that, in addition to the previously described mechanisms leading to reduced p27KIP1 activity, such as degradation via the ubiquitin/proteasome pathway or non-covalent sequestration, p27KIP1 activity can also be modulated by an uORF and mutations affecting uORF could change p27KIP1 expression. This study adds the CDKN1B gene to the short list of genes for which mutations that either create, delete, or severely modify their regulatory uORFs have been associated with human diseases. Gene expression can be modulated at different steps on the way from DNA to protein including control of transcription, translation, and post-translational modifications. An abnormality in the regulation of mRNA and protein expression is a hallmark of many human diseases, including cancer. In some eukaryotic genes translation can be influenced by small DNA sequences termed upstream open reading frames (uORFs). These elements located upstream to the gene start codon may either negatively influence the ability of the translational machinery to reinitiate translation of the main protein or, much less frequently, stimulate protein translation by enabling the ribosomes to bypass cis-acting inhibitory elements. CDKN1B, which encodes the cell cycle inhibitor p27KIP1, includes an uORF in its 5′UTR sequence. p27KIP1 expression is often reduced in cancer, and germline mutations have been identified in CDKN1B in patients affected with a syndrome (MEN4) characterized by varying combinations of tumors in endocrine glands. Here we show that a small deletion in the uORF upstream to CDKN1B reduces translation reinitiation efficiency, leading to underexpression of p27KIP1 and coinciding with tumorigenesis. This study describes a novel mechanism by which p27KIP1 could be underexpressed in human tumors. In addition, our data provide a new insight to the unique pathogenic potential of uORFs in human diseases.

15 January 2013 in Journal of Bioactive and Compatible Polymers
Verified
Journal Article
Closed access
PDF file
MSMatteo Stoppato
Matteo Stoppato
ECEleonora Carletti
Eleonora Carletti
VSViktoryia Sidarovich
Viktoryia Sidarovich
AQAlessandro Quattrone
Alessandro Quattrone
RURonald E Unger
Ronald E Unger
Antonella MottaAntonella Motta
Antonella Motta
Bone tissue engineering takes part in the complex process of bone healing by combining cells, chemical/physical signals, and scaffolds with the scaffolds providing an artificial extracellular matrix network. The role of the support template for cell activity is crucial to guide the healing process. This in vitro study compared three different poly(D,L-lactic acid) scaffolds obtained by varying the pore size generated by applying different salt leaching processes. The influence of pore dimensions on the extracellular matrix produced by human osteosarcoma-derived osteoblasts (MG63 cell line) seeded on these different materials was analyzed. This study is targeted on the intermediate stage of the bone healing process, where a collagen network is beginning to develop by the growing osteoblasts representing the template for the ultimate stage of bone formation. Imaging analyses assessed by confocal laser microscopy were combined with gene expression measurements of the most common genes involved in the bone healing process. Furthermore, in vitro evaluations were carried out to investigate cell morphology, proliferation, and viability. It was found that the different pore size matrixes can affect extracellular matrix development and that cell organization, collagen I assembly, and mineralization are strictly correlated.

1 January 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SASanja Aveic
Sanja Aveic
DCDiana Corallo
Diana Corallo
EPElena Porcú
Elena Porcú
MPMarcella Pantile
Marcella Pantile
DBDaniele Boso
Daniele Boso
GTGian Paolo Tonini
Gian Paolo Tonini

1 July 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
VSViktoryia Sidarovich
Viktoryia Sidarovich
MMMarilena De Mariano
Marilena De Mariano
SASanja Aveic
Sanja Aveic
MPMichael Pancher
Michael Pancher
VAValentina Adami
Valentina Adami
LLLuca Longo
Luca Longo
Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anticancer compounds library. In the primary screening, we employed three NB cell lines, grown as three-dimensional (3D) multicellular spheroids, which were treated with 10 μmol/L of the library compounds for 72 hours. The viability of 3D spheroids was evaluated using a high-content imaging approach, resulting in a primary hit list of 193 compounds. We selected 60 FDA-approved molecules and prioritized drugs with multi-target activity, discarding those already in use for NB treatment or enrolled in NB clinical trials. Hence, 20 drugs were further tested for their efficacy in inhibiting NB cell viability, both in two-dimensional and 3D models. Dose-response curves were then supplemented with the data on side effects, therapeutic index, and molecular targets, suggesting two multiple tyrosine kinase inhibitors, ponatinib and axitinib, as promising candidates for repositioning in NB. Indeed, both drugs showed induction of cell-cycle block and apoptosis, as well as inhibition of colony formation. However, only ponatinib consistently affected migration and inhibited invasion of NB cells. Finally, ponatinib also proved effective inhibition of tumor growth in orthotopic NB mice, providing the rationale for its repurposing in NB therapy. Mol Cancer Ther; 17(7); 1405–15. ©2018 AACR.

24 April 2018 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
SASanja Aveic
Sanja Aveic
MPMarcella Pantile
Marcella Pantile
PPPierfrancesco Polo
Pierfrancesco Polo
VSViktoryia Sidarovich
Viktoryia Sidarovich
MMMarilena De Mariano
Marilena De Mariano
GTGian Paolo Tonini
Gian Paolo Tonini
A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation. Deregulated activity of RTKs in tumors can determine disease progression and therapeutic responses in several types of cancer, including neuroblastoma (NB). Therefore, RTKs targeting is a worthwhile challenge for the oncologists. Nevertheless, acquired resistance to RTK inhibitors (RTKi) remains a serious problem. Autophagy activation is among the possible obstacles for good efficacy of the therapy with RTKi. Under different treatment conditions we measured autophagic flux using immunoblot and immunofluorescence assays. Death induction was validated by trypan blue exclusion assay and FACS analysis (calcein-AM/propidium iodide). The NB cell lines SH-SY5Y and Kelly were used for the in vitro study. In order to define whether autophagy might be a limiting factor for the efficacy of RTKi in NB cells, we firstly checked its activation following the treatment with several RTKi. Next, we investigated the possibility to increase their therapeutic efficiency by combining RTKi with autophagy blocking agents in vitro. We exploited the effectiveness of three RTKi either alone or in combination with autophagy inhibitors (Chloroquine—CQ and Spautin-1). We demonstrated that autophagy induction was drug-dependent, and that its inhibition increased the anti-tumor activity of a single RTKi unevenly. We observed that the combined use of blocking agents which impair late autophagy events, such as CQ, and RTKi can be more effective with respect to the use of RTKi alone. In the present report, we assessed the conditions under which autophagy is activated during the use of different RTKi currently in the pre-clinical evaluation for NB. We summarized the achievements of combined RTK/autophagy inhibitors treatment as a promising approach to enhance the efficacy of RTKi in impairing tumor cells viability.

1 March 2015 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
VSViktoryia Sidarovich
Viktoryia Sidarovich
VAValentina Adami
Valentina Adami
PGPamela Gatto
Pamela Gatto
VGValentina Greco
Valentina Greco
TTToma Tebaldi
Toma Tebaldi
AQAlessandro Quattrone
Alessandro Quattrone
Iron is an essential cellular nutrient, being a critical cofactor of several proteins involved in cell growth and replication. Compared with normal cells, neoplastic cells have been shown to require a greater amount of iron, thus laying the basis for the promising anticancer activity of iron chelators. In this work, we evaluated the effects of molecules with iron chelation activity on neuroblastoma (NB) cell lines. Of the 17 iron chelators tested, six reduced cell viability of two NB cell lines with an inhibition of growth of 50% below 10 µM; four of the six molecules—ciclopirox olamine (CPX), piroctone, 8-hydroxyquinoline, and deferasirox—were also shown to efficiently chelate intracellular iron within minutes after addition. Effects on cell viability of one of the compounds, CPX, were indeed dependent on chelation of intracellular iron and mediated by both G0/G1 cell cycle block and induction of apoptosis. By combined transcriptome and translatome profiling we identified early translational downregulation of several members of the heat shock protein group as a specific effect of CPX treatment. We functionally confirmed iron-dependent depletion of HSP90 and its client proteins at pharmacologically achievable concentrations of CPX, and we extended this effect to piroctone, 8-hydroxyquinoline, and deferasirox. Given the documented sensitivity of NB cells to HSP90 inhibition, we propose CPX and other iron chelators as investigational antitumor agents in NB therapy.